Pelcitoclax (APG-1252) is a potent Bcl-2/Bcl-xl inhibitor with antineoplastic and pro-apoptotic effects[1].

APG-1252 changes to the reactive metabolite named APG-1252-M1, which has remarkable antitumor effects in acute myeloid leukemia[1].

Pelcitoclax (APG-1252; 25-100 mg/kg; i.v.; once a day; for 10days) treatment inhibits xenograft tumor growth more obviously than the other groups[1].

1619923-36-2

C57H66ClF4N6O11PS4

1281.85

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years